Photo from wikipedia
A three-drug regimen containing the CTLA4 inhibitor tremelimumab plus the PD-L1 inhibitor durvalumab and chemotherapy may be an effective first-line treatment strategy for patients with metastatic non-small cell lung cancer.… Click to show full abstract
A three-drug regimen containing the CTLA4 inhibitor tremelimumab plus the PD-L1 inhibitor durvalumab and chemotherapy may be an effective first-line treatment strategy for patients with metastatic non-small cell lung cancer. In the phase III POSEIDON trial, the combination significantly extended progression-free survival and overall survival compared with chemotherapy alone.
Keywords:
three drug;
drug regimen;
chemo nsclc;
bests chemo;
regimen bests
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!